Top Page
Jubilant Pharmova Limited
(JUBLPHARMA)
Jubilant Pharmova Limited (JUBLPHARMA) vs. iShares MSCI India ETF (INDA)
Jubilant Pharmova Limited Business Overview & Revenue Model
Jubilant Pharmova Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 74.03B | 72.34B | 67.03B | 62.82B | 61.30B | 60.99B |
| Gross Profit | 48.11B | 46.99B | 43.52B | 42.00B | 46.42B | 45.63B |
| EBITDA | 11.46B | 10.48B | 7.93B | 6.46B | 10.66B | 14.68B |
| Net Income | 4.60B | 8.39B | 771.00M | -610.00M | 4.14B | 8.36B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 127.56B | 115.48B | 111.57B | 99.91B | 89.18B |
| Cash, Cash Equivalents and Short-Term Investments | 10.89B | 10.89B | 9.56B | 10.15B | 9.86B | 6.89B |
| Total Debt | 0.00 | 27.31B | 36.64B | 36.77B | 31.92B | 28.30B |
| Total Liabilities | -62.39B | 65.18B | 61.27B | 57.65B | 46.74B | 41.77B |
| Stockholders Equity | 62.39B | 62.55B | 54.34B | 53.99B | 53.19B | 47.41B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -435.00M | 736.00M | -1.54B | 2.38B | 12.57B |
| Operating Cash Flow | 0.00 | 10.72B | 9.71B | 6.61B | 8.38B | 17.84B |
| Investing Cash Flow | 0.00 | 4.88B | -6.08B | -5.44B | -3.80B | -7.39B |
| Financing Cash Flow | 0.00 | -14.53B | -4.33B | -1.57B | -325.99M | -17.09B |
Jubilant Pharmova Limited Technical Analysis
Jubilant Pharmova Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹159.47B | 10.36 | ― | 0.57% | -3.79% | -20.88% | |
73 Outperform | ₹146.16B | 28.49 | ― | 0.24% | 8.14% | 5.18% | |
69 Neutral | ₹137.81B | 23.41 | ― | 0.31% | 11.41% | 19.22% | |
67 Neutral | ₹189.58B | 78.94 | ― | 0.08% | 0.34% | -14.13% | |
62 Neutral | ₹169.23B | 35.23 | ― | 0.46% | 10.09% | -19.40% | |
60 Neutral | ₹157.23B | 24.78 | ― | 1.28% | 11.42% | -1.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Jubilant Pharmova Limited Corporate Events
Jubilant Pharmova’s step-down subsidiary, Jubilant Generics Limited, has invested CAD 30,000 (about INR 0.20 crore) in Jubilant Pharmaceuticals Inc., a newly incorporated Canadian entity that will operate in the pharmaceuticals industry and is yet to commence business operations. With this initial cash investment, Jubilant Pharmaceuticals Inc. becomes a step-down wholly owned subsidiary, providing the group a direct platform to build a branded generics business in Canada, strengthen its presence in the Canadian market, and support future revenue growth without requiring additional regulatory approvals for the acquisition.
Jubilant Pharmova has disclosed that its wholly owned subsidiary, Jubilant Biosys Limited, has received an order from the Joint Commissioner of GST in Noida confirming a Goods and Services Tax demand of Rs 6.98 crore and a penalty of Rs 2.72 crore for the financial years 2020-21 to 2022-23, arising from alleged discrepancies in input tax credit claims. The company contends that the demand is legally untenable and based on frivolous grounds despite prior submission of documents, and it plans to challenge the order before the Commissioner (Appeals); management maintains that the case has strong merits, and asserts there will be no material impact on the group’s financials, operations or other activities, suggesting limited immediate risk for shareholders and other stakeholders.
Jubilant Pharmova Limited has announced that its wholly owned subsidiary, Jubilant Biosys Limited, received an Adjudication Order from the Deputy Commissioner of Commercial Taxes, Mysuru, concerning a demand for GST, interest, and penalty for the financial year 2021-2022. The company plans to file an appeal against the order, arguing that it is legally incorrect and expects no financial or operational impact from the order.
Jubilant Pharmova Limited has appointed Daniel J. O’Connor as the CEO of its subsidiary, Jubilant Therapeutics Inc. O’Connor brings over 30 years of experience in biotechnology and oncology, having previously increased company valuations and led successful acquisitions. His leadership is expected to advance Jubilant’s mission to develop innovative cancer therapies, potentially impacting stakeholders positively by driving breakthrough innovations in difficult-to-treat cancers.
Jubilant Pharmova Limited has launched the ‘Saksham Niveshak’ campaign, a 100-day initiative aimed at reminding shareholders about unpaid or unclaimed dividends. This campaign signifies the company’s proactive approach in engaging with its shareholders and ensuring that they receive their due entitlements, potentially strengthening shareholder relations and trust.
Jubilant Pharmova Limited has announced the publication of its unaudited standalone and consolidated financial results for the quarter and half year ending September 30, 2025. These results, approved by the Board of Directors, are accessible to investors through newspaper publications and the company’s website, reflecting the company’s commitment to transparency and regulatory compliance.
Jubilant Pharmova Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025. The results, approved by the Board of Directors, were prepared in compliance with Indian Accounting Standards and SEBI regulations. The review by independent auditors concluded that the financial statements were presented fairly without any material misstatements, indicating stable financial management and compliance with regulatory standards.
Jubilant Pharmova Limited’s Board of Directors has approved the grant of 1,506 Stock Options/Restricted Stock Units (RSUs) to eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting employee motivation and aligning their interests with the company’s long-term goals.
Jubilant Pharmova Limited has announced the approval of 1,506 Stock Options/Restricted Stock Units (RSUs) for eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market positioning positively.
Jubilant Pharmova Limited has launched an initiative as part of the ‘Saksham Niveshak – 100 Days Campaign’ to assist shareholders in updating their KYC details and claiming unpaid dividends. This campaign, directed by the Ministry of Corporate Affairs, aims to prevent the transfer of unclaimed dividends and shares to the Investor Education and Protection Fund Authority, ensuring shareholders secure their entitlements.
Jubilant Pharmova Limited has issued a second communication to its shareholders regarding the transfer of equity shares to the Investor Education and Protection Fund (IEPF). This move is in compliance with the Companies Act, 2013, and the IEPF Rules, which mandate the transfer of shares for which dividends have not been claimed for seven consecutive years. The company has reminded shareholders that unclaimed dividends from the financial year 2017-18 are due for transfer to the IEPF by November 1, 2025, unless there are specific legal restrictions. This action ensures compliance with regulatory requirements and affects shareholders who have not claimed their dividends, potentially impacting their equity holdings.
Jubilant Pharmova Limited has announced the publication of a newspaper advertisement related to several shareholder initiatives. These include the launch of the ‘Saksham Niveshak’ campaign by the Investor Education and Protection Fund Authority, a special window for re-lodgement of transfer requests for physical shares, and the updating of KYC and dematerialization of physical share certificates. This announcement is part of the company’s ongoing efforts to enhance shareholder engagement and streamline share-related processes.